Clinical Trials Browser

Has results × tremelimumab × Dermatologic × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed

37 enrolled 13 charts

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT00471887 2020-10-26

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Phase 2 Completed

32 enrolled 15 charts

Dermatologic

Melanoma

NCT00610857 2017-06-22

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Phase 2 Completed

37 enrolled 8 charts

Dermatologic

Melanoma

Clinical Trials

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma